En Es
Categories

Industry News

DiaSorin to Acquire Luminex to Broaden Positioning in Molecular Diagnostics Space

By Labmedica International staff writers
13 Apr 2021

Image: The Luminex Aries® System (Photo courtesy of Luminex Corporation)DiaSorin S.p.A. (?Saluggia?, Italy) has announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation (Austin, TX, USA) for approximately USD 1.8 billion.

Luminex develops, manufactures and sells proprietary biological testing technologies and products with leading applications throughout the Diagnostics and Life Science industries. Luminex is a leader in multiplexing technology, one of the fastest growing markets in the molecular space, with more than 900 active clients. With its first-class technology and extensive Life Science solutions supporting clinical and pharmaceutical research and development, Luminex is highly complementary to DiaSorin's growing diagnostics segment.

The acquisition will broaden DiaSorin's positioning in the molecular diagnostics space and strengthen its existing value proposition in line with its strategic priorities. Through the acquisition, DiaSorin will gain access to Luminex's molecular diagnostics multiplexing technology and a portfolio that will strengthen its existing offering while expanding its presence in the US. The acquisition will also provide access to Luminex's applications throughout the Life Science industry, supporting access to academic and scientific research to shape market intelligence on future market trends, engaging with biopharma companies to drive opportunities for long-term partnerships (e.g. vaccine development, biological drugs) and access to clinical multiplexing assays for future Value Based Care projects based on diagnostic algorithms.

"Luminex perfectly fits with our strategy to grow our positioning in the molecular diagnostics space, to broaden our presence in the US, and to create additional value through Life Science offerings," said Carlo Rosa, CEO of DiaSorin Group. "Together, DiaSorin and Luminex will provide a unique offer to laboratories, researchers, clinicians and patients worldwide, matching our extensive solutions in immunodiagnostics and molecular diagnostics with Luminex's outstanding expertise in multiplexing technology and recognized leadership in life science applications."

"The combined company should provide new opportunities for our employees within a larger company that is poised to become a strong leader in the molecular diagnostics and life sciences space, and I want to thank all of our employees, customers, and partners for their contributions over our 25+ year history," said Nachum "Homi" Shamir, Chairman, President and CEO of Luminex.


Related Links:
DiaSorin S.p.A.
Luminex Corporation




E-mail Print
FaceBook Twitter Google+ Linked in

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics, pharmaceutical drug discovery, biomedical research, including genomic and proteomic research, personalized medicine, biodefense research, and food safety. The company’s open-architecture xMAP technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.
More info

More articles about Luminex Corporation

16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More

Additional news

18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
11 Jan 2022
J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions
The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA; www.microsoft.com) to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem.
Read More
10 Jan 2022
ICU Medical Completes Acquisition of Smiths Medical to Create Leading Infusion Therapy Company
ICU Medical Inc. (San Clemente, CA, USA) has completed its acquisition of Smiths Medical (Minneapolis, MN, USA) from Smiths Group plc that includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies create a leading infusion therapy company.
Read More
05 Jan 2022
Global Portable Ultrasound Scanner Market to Be Driven by Rising Trauma and Accident Cases
The global portable ultrasound scanner market is being driven by an increase in targeted illnesses, rise in trauma & accident cases, surge in demand for less invasive operations, and the emergence of a senior population at a high risk of diseases.
Read More
04 Jan 2022
Global Mammography Workstations Market to Surpass USD 0.19 Billion in 2028 Due to Increasing Prevalence of Breast Cancer
The global mammography workstations market is projected to grow at a CAGR of 6.8% from about USD 0.12 billion in 2020 to more than USD 0.19 billion in 2028, led by increasing prevalence of breast cancer across the world, growing need for early breast cancer diagnosis and treatment, rise in government initiatives to spread breast cancer awareness, and rapid adoption of advanced mammography workstations in hospitals, clinics, and breast care centers.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions